China’s Innovative Medical Devices Hit Record 431 Cumulative Approvals — 40 New in 2026

On June 27, 2026, the China Federation of Logistics and Purchasing released the China Medical Device Supply Chain Development Report (2026), revealing that the cumulative number of innovative medical devices approved by the National Medical Products Administration (NMPA) has reached 431 as of June 18, 2026, with 40 new approvals added in 2026 alone — a new historic high for annual additions.

Key Findings

•Total innovative device approvals: 431 (as of June 18, 2026)

•New approvals in 2026: 40 — surpassing previous annual records

•2025 industrial market size: RMB 12,049.84 billion (approximately USD 1.68 trillion), with year-on-year growth of 1.12%, maintaining a steady upward trajectory

•Warehousing infrastructure: National medical device logistics warehousing total area reached 23,821,400 square meters at the end of 2025, up 1.02% year-on-year

The report highlights that China’s medical device industry continues to demonstrate robust innovation momentum and technical breakthrough capabilities. NMPA has progressively simplified the registration process for innovative medical devices, with approval timelines compressed to within six months, enabling faster commercialization of cutting-edge products.

Regulatory Context

NMPA’s accelerating approval pace reflects a broader policy push to foster domestic innovation and reduce reliance on imported high-end devices. On June 1, 2026, NMPA issued the Notice on Medical Device Classification Adjustment and the Medical Device Classification Catalog Dynamic Adjustment Working Procedure, further optimizing the classification framework to support innovation.

Additionally, public hospital procurement mandates are increasingly favoring domestically produced devices, while volume-based procurement (VBP) rules have been refined to include a 30-day payment guarantee and stepped procurement volumes, substantially improving manufacturer cash flow.

Industry Perspective

The 40 new innovative approvals span multiple high-value segments including cardiac assist devices, surgical robots, brain-computer interfaces, and advanced diagnostic systems, signaling that China’s medtech innovation is moving beyond incremental improvements toward globally competitive breakthroughs.